Protalix BioTherapeutics Expands Partnership with Chiesi Farmaceutici to Include Exclusive U.S. Rights for the Development and Commercialization of PRX-102; Co. To Receive $25M Up Front, $20M In Development Costs, And $760M In Potential Milestones
Benzinga_Newsdesk